Recent advances in treatment of nodal and gastrointestinal follicular lymphoma

Table 2 Summary of clinical trial results of bispecific T cell binding antibody therapies

Study	Target disease	No.of patients	Objective response rate	Complete response rate	Median progression-free survival	Overall survival	Adverse events or other subjects	Ref.
Mosunetuzumab alone, phase-I	r/r NHL (including FL and t-FL)	n = 157	66.2% (i B-NHL)	48.5% (i B-NHL)	Median duration of response 20.4 mo (i B-NHL	Unknown	G3 and higher in 71% of iNHL patients	[24]
Mosunetuzumab alone, phase-II	r/r FL (Grade 1-3a)	n = 90 (median follow-up was 18.3 mo)	Unknown	60% (n = 54/90) (14% higher than CRR with copanlisib), high efficacy	Unknown	Unknown	High efficacy	[25]
Mosunetuzumab with lenaridomide, phase-I	r/r FL	Unknown	92%	77%	Unknown	Unknown	G3 and higher in 30% of patients	In abstruct
Glofitamab alone, phase-I	r/r B-NHL (including r/r FL)	n = 155	65.7% (at the recommended phase-II dose)	57.1% (at the recommended phase-II dose)	Unknown	Unknown	CRS occurred in 50.3% of patients	[26]
Glofitamab alone vs glofitamab with obinutuzumab	r/r FL	Unknown	81%, 100%	70%, 74%	Unknown	Unknown	Combination has a better response rate	In Abstruct
Epcoritamab, phase-I/II	r/r B-NHL	n = 68	90% (full dose)	50% (full dose)	Unknown	Unknown	Pyrexia 69%, CRS 59%	[27]
Epcoritamab with lenaridomide and rituximab	r/r FL	Unknown	100%	93%	Unknown	Unknown	High efficacy is revealed	[28]
Odronextamab alone phase-I ELM-1 trial	r/r B-NHL (including r/r FL)	n = 145	91% (r/r FL)	72% (r/r FL)	Unknown	Unknown	CRS 28%	[29]

“Unknown” means data not shown, unknown information or not reached. r/r: Refractory and relapsed; (i)NHL: (Indolent) non-Hodgkin lymphoma; i B-NHL: Indolent B-cell non-Hodgkin lymphoma; FL: Follicular lymphoma; t-FL: Transformed follicular lymphoma; G: Grade; CRS: Cytokine release syndrome.